Action Science 37 - SNCE

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

5,75

Prix Achat

5,72

Prix Vente

5,74

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

5,75

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient...

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline...

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in...

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the...

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

SNCE - Frequently Asked Questions (FAQ)

What is the current Science 37 share price?

The current share price of Science 37 is US$ 5,75

What is the 1 year trading range for Science 37 share price?

Science 37 has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MLGOMicroAlgo Inc	US$ 2,00 (73,91%)	8,86M
UPCUniverse Pharmaceuticals Inc	US$ 0,1866 (30,95%)	18,8M
CELHCelsius Holdings Inc	US$ 33,16 (29,89%)	9,47M
GDYNGrid Dynamics Holdings Inc	US$ 24,14 (17,87%)	47,56k
HOLOMicroCloud Hologram Inc	US$ 1,39 (16,81%)	4,57M
AXTIAXT Inc	US$ 1,77 (-22,71%)	256,2k
CNTMConnectM Technology Solutions Inc	US$ 0,7788 (-16,26%)	419,16k
APTOAptose Biosciences Inc	US$ 0,16 (-15,79%)	1,21M
MCVTMill City Ventures III Ltd	US$ 1,95 (-15,22%)	92,06k
CARGCarGurus Inc	US$ 33,50 (-10,88%)	52,28k
UPCUniverse Pharmaceuticals Inc	US$ 0,1866 (30,95%)	18,8M
RIVNRivian Automotive Inc	US$ 14,34 (5,36%)	10,1M
CELHCelsius Holdings Inc	US$ 33,16 (29,89%)	9,47M
MLGOMicroAlgo Inc	US$ 2,00 (73,91%)	8,86M
MNDRMobile health Network Solutions	US$ 0,872801 (-7,14%)	8,27M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Science 37 Holdings Inc (SNCE)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNCE Dernières nouvelles

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

SNCE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Science 37 Holdings Inc (SNCE) Cours

Science 37 Holdings Inc (SNCE)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNCE Dernières nouvelles

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

SNCE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS